Skip to main content

Advertisement

SpringerLink
Log in

Picalm reduction exacerbates tau pathology in a murine tauopathy model

  • Original Paper
  • Published:
Acta Neuropathologica Aims and scope Submit manuscript

Abstract

Genome-wide association studies (GWAS) have identified PICALM as one of the most significant susceptibility loci for late-onset Alzheimer’s disease (AD) after APOE and BIN1. PICALM is a clathrin-adaptor protein and plays critical roles in clathrin-mediated endocytosis and in autophagy. PICALM modulates brain amyloid ß (Aß) pathology and tau accumulation. We have previously reported that soluble PICALM protein level is reduced in correlation with abnormalities of autophagy markers in the affected brain areas of neurodegenerative diseases including AD, sporadic tauopathies and familial cases of frontotemporal lobar degeneration with tau-immunoreactive inclusions (FTLD-tau) with mutations in the microtubule-associated protein tau (MAPT) gene. It remains unclarified whether in vivo PICALM reduction could either trigger or influence tau pathology progression in the brain. In this study, we confirmed a significant reduction of soluble PICALM protein and autophagy deficits in the post-mortem human brains of FTLD-tau-MAPT (P301L, S364S and L266V). We generated a novel transgenic mouse line named Tg30xPicalm+/− by crossing Tg30 tau transgenic mice with Picalm-haploinsufficient mice to test whether Picalm reduction may modulate tau pathology. While Picalm haploinsufficiency did not lead to any motor phenotype or detectable tau pathology in mouse brains, Tg30xPicalm+/−  mice developed markedly more severe motor deficits than Tg30 by the age of 9 months. Tg30xPicalm+/−  had significantly higher pathological tau levels in the brain, an increased density of neurofibrillary tangles compared to Tg30 mice and increased abnormalities of autophagy markers. Our results demonstrate that Picalm haploinsufficiency in transgenic Tg30 mice significantly aggravated tau pathologies and tau-mediated neurodegeneration, supporting a role for changes in Picalm expression as a risk/sensitizing factor for development of tau pathology and as a mechanism underlying the AD risk associated to PICALM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Adamec E, Mohan P, Vonsattel JP, Nixon RA (2002) Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2. Acta Neuropathol 104:92–104

    CAS  PubMed  Google Scholar 

  2. Ahmed Z, Bigio EH, Budka H, Dickson DW, Ferrer I, Ghetti B et al (2013) Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathol 126:537–544

    PubMed  PubMed Central  Google Scholar 

  3. Ando K, Brion JP, Stygelbout V, Suain V, Authelet M, Dedecker R et al (2013) Clathrin adaptor CALM/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimer's brains. Acta Neuropathol 125:861–878

    CAS  PubMed  Google Scholar 

  4. Ando K, Kabova A, Stygelbout V, Leroy K, Heraud C, Frederick C et al (2014) Vaccination with sarkosyl insoluble PHF-Tau decrease neurofibrillary tangles formation in aged tau transgenic mouse model: a pilot study. J Alzheimers Dis 40:S135–S145

    PubMed  Google Scholar 

  5. Ando K, Leroy K, Heraud C, Yilmaz Z, Authelet M, Suain V et al (2011) Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. Am J Pathol 178:803–816

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Ando K, Tomimura K, Sazdovitch V, Suain V, Yilmaz Z, Authelet M et al (2016) Level of PICALM, a key component of clathrin-mediated endocytosis, is correlated with levels of phosphotau and autophagy-related proteins and is associated with tau inclusions in AD, PSP and Pick disease. Neurobiol Dis 94:32–43

    CAS  PubMed  Google Scholar 

  7. Arioka M, Tsukamoto M, Ishiguro K, Kato R, Sato K, Imahori K et al (1993) Tau protein kinase II is involved in the regulation of the normal phosphorylation state of tau protein. J Neurochem 60:461–468

    CAS  PubMed  Google Scholar 

  8. Brion JP, Hanger DP, Bruce MT, Couck AM, Flament-Durand J, Anderton BH (1991) Tau in Alzheimer neurofibrillary tangles. N- and C-terminal regions are differentially associated with paired helical filaments and the location of a putative abnormal phosphorylation site. Biochem J 273:127–133

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Brion JP, Hanger DP, Couck AM, Anderton BH (1991) A68 proteins in Alzheimer's disease are composed of several tau isoforms in a phosphorylated state which affects their electrophoretic mobilities. Biochem J 279(Pt 3):831–836

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Broce I, Karch CM, Wen N, Fan CC, Wang Y, Tan CH et al (2018) Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Med 15:e1002487

    PubMed  PubMed Central  Google Scholar 

  11. Chapuis J, Hansmannel F, Gistelinck M, Mounier A, Van Cauwenberghe C, Kolen KV et al (2013) Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol Psychiatry 18:1225–1234

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A et al (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11:909–913

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Crotti A, Sait HR, McAvoy KM, Estrada K, Ergun A, Szak S et al (2019) BIN1 favors the spreading of Tau via extracellular vesicles. Sci Rep 9:9477

    PubMed  PubMed Central  Google Scholar 

  14. Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40:471–483

    CAS  PubMed  Google Scholar 

  15. Dourlen P, Fernandez-Gomez FJ, Dupont C, Grenier-Boley B, Bellenguez C, Obriot H et al (2017) Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology. Mol Psychiatry 22:874–883

    CAS  PubMed  Google Scholar 

  16. Ferreira A, Bigio EH (2011) Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies. Mol Med 17:676–685

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Forrest SL, Kril JJ, Stevens CH, Kwok JB, Hallupp M, Kim WS et al (2018) Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. Brain 141:521–534

    PubMed  Google Scholar 

  18. Frederick C, Ando K, Leroy K, Heraud C, Suain V, Buee L et al (2015) Rapamycin ester analog CCI-779/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice. J Alzheimers Dis 44:1145–1156

    CAS  PubMed  Google Scholar 

  19. Goedert M, Jakes R, Vanmechelen E (1995) Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett 189:167–169

    CAS  PubMed  Google Scholar 

  20. Greenberg SG, Davies P (1990) A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA 87:5827–5831

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Grynspan F, Griffin WR, Cataldo A, Katayama S, Nixon RA (1997) Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease. Brain Res 763:145–158

    CAS  PubMed  Google Scholar 

  22. Hang HC, Linder ME (2011) Exploring protein lipidation with chemical biology. Chem Rev 111:6341–6358

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15:112–119

    CAS  PubMed  Google Scholar 

  24. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41:1088–1093

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Hasegawa M, Jakes R, Crowther RA, Lee VM, Ihara Y, Goedert M (1996) Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. FEBS Lett 384:25–30

    CAS  PubMed  Google Scholar 

  26. Huang YA, Zhou B, Wernig M, Sudhof TC (2017) ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and abeta secretion. Cell 168(427–441):e421

    Google Scholar 

  27. Kanatsu K, Morohashi Y, Suzuki M, Kuroda H, Watanabe T, Tomita T et al (2014) Decreased CALM expression reduces Abeta42 to total Abeta ratio through clathrin-mediated endocytosis of gamma-secretase. Nat Commun 5:3386

    PubMed  Google Scholar 

  28. Kim JA, Kim HL (2001) Cleavage of purified neuronal clathrin assembly protein (CALM) by caspase 3 and calpain. Exp Mol Med 33:245–250

    CAS  PubMed  Google Scholar 

  29. Kobayashi T, Ota S, Tanaka K, Ito Y, Hasegawa M, Umeda Y et al (2003) A novel L266V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology. Ann Neurol 53:133–137

    CAS  PubMed  Google Scholar 

  30. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I et al (2006) Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441:880–884

    CAS  PubMed  Google Scholar 

  31. Kuninaka N, Kawaguchi M, Ogawa M, Sato A, Arima K, Murayama S et al (2015) Simplification of the modified Gallyas method. Neuropathology 35:10–15

    PubMed  Google Scholar 

  32. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41:1094–1099

    CAS  PubMed  Google Scholar 

  33. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 45:1452–1458

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405:360–364

    CAS  PubMed  Google Scholar 

  35. Leroy K, Bretteville A, Schindowski K, Gilissen E, Authelet M, De Decker R et al (2007) Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am J Pathol 171:976–992

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Li T, Hawkes C, Qureshi HY, Kar S, Paudel HK (2006) Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. Biochemistry 45:3134–3145

    CAS  PubMed  Google Scholar 

  37. Miller SE, Mathiasen S, Bright NA, Pierre F, Kelly BT, Kladt N et al (2015) CALM regulates clathrin-coated vesicle size and maturation by directly sensing and driving membrane curvature. Dev Cell 33:163–175

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Moreau K, Fleming A, Imarisio S, Lopez Ramirez A, Mercer JL, Jimenez-Sanchez M et al (2014) PICALM modulates autophagy activity and tau accumulation. Nat Commun 5:4998

    CAS  PubMed  Google Scholar 

  39. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71:362–381

    PubMed  Google Scholar 

  40. Nixon RA (2013) The role of autophagy in neurodegenerative disease. Nat Med 19:983–997

    CAS  PubMed  Google Scholar 

  41. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J et al (2003) Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38:555–565

    CAS  PubMed  Google Scholar 

  42. Otvos L Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 39:669–673

    CAS  PubMed  Google Scholar 

  43. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402:615–622

    CAS  PubMed  Google Scholar 

  44. Plattner F, Angelo M, Giese KP (2006) The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 281:25457–25465

    CAS  PubMed  Google Scholar 

  45. Popovic M, Fabjan A, Mraz J, Magdic J, Glavac D, Zupan A et al (2014) Tau protein mutation P364S in two sisters: clinical course and neuropathology with emphasis on new, composite neuronal tau inclusions. Acta Neuropathol 128:155–157

    PubMed  Google Scholar 

  46. Rudinskiy N, Grishchuk Y, Vaslin A, Puyal J, Delacourte A, Hirling H et al (2009) Calpain hydrolysis of alpha- and beta2-adaptins decreases clathrin-dependent endocytosis and may promote neurodegeneration. J Biol Chem 284:12447–12458

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Saito K, Elce JS, Hamos JE, Nixon RA (1993) Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci USA 90:2628–2632

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M (2012) Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain 135:2169–2177

    PubMed  PubMed Central  Google Scholar 

  49. Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M et al (2006) Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169:599–616

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Sengupta A, Wu Q, Grundke-Iqbal I, Iqbal K, Singh TJ (1997) Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol Cell Biochem 167:99–105

    CAS  PubMed  Google Scholar 

  51. Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W et al (2017) ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549:523–527

    PubMed  PubMed Central  Google Scholar 

  52. Snyder SW, Ladror US, Wade WS, Wang GT, Barrett LW, Matayoshi ED et al (1994) Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J 67:1216–1228

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong LM, Jakes R et al (1994) Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci USA 91:11183–11186

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Su JH, Zhao M, Anderson AJ, Srinivasan A, Cotman CW (2001) Activated caspase-3 expression in Alzheimer's and aged control brain: correlation with Alzheimer pathology. Brain Res 898:350–357

    CAS  PubMed  Google Scholar 

  55. Suzuki M, Tanaka H, Tanimura A, Tanabe K, Oe N, Rai S et al (2012) The clathrin assembly protein PICALM is required for erythroid maturation and transferrin internalization in mice. PLoS ONE 7:e31854

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Taskesen E, Mishra A, van der Sluis S, Ferrari R, International FTDGC, Veldink JH et al (2017) Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS. Sci Rep 7:8899

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Tebar F, Bohlander SK, Sorkin A (1999) Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell 10:2687–2702

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Tian Y, Chang JC, Fan EY, Flajolet M, Greengard P (2013) Adaptor complex AP2/PICALM, through interaction with LC3, targets Alzheimer's APP-CTF for terminal degradation via autophagy. Proc Natl Acad Sci USA 110:17071–17076

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Tian Y, Chang JC, Greengard P, Flajolet M (2014) The convergence of endosomal and autophagosomal pathways: implications for APP-CTF degradation. Autophagy 10:694–696

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Tsuji T, Shimohama S, Kimura J, Shimizu K (1998) m-Calpain (calcium-activated neutral proteinase) in Alzheimer's disease brains. Neurosci Lett 248:109–112

    CAS  PubMed  Google Scholar 

  61. Vergara C, Houben S, Suain V, Yilmaz Z, De Decker R, Vanden Dries V et al (2019) Amyloid-beta pathology enhances pathological fibrillary tau seeding induced by Alzheimer PHF in vivo. Acta Neuropathol 137:397–412

    CAS  PubMed  Google Scholar 

  62. Wang Y, Martinez-Vicente M, Kruger U, Kaushik S, Wong E, Mandelkow EM et al (2009) Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet 18:4153–4170

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Wojtas AM, Kang SS, Olley BM, Gatherer M, Shinohara M, Lozano PA et al (2017) Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways. Proc Natl Acad Sci USA 114:E6962–E6971

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Wu JW, Herman M, Liu L, Simoes S, Acker CM, Figueroa H et al (2013) Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem 288:1856–1870

    CAS  PubMed  Google Scholar 

  65. Zhao Z, Sagare AP, Ma Q, Halliday MR, Kong P, Kisler K et al (2015) Central role for PICALM in amyloid-beta blood-brain barrier transcytosis and clearance. Nat Neurosci 18:978–987

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Zhou Y, Hayashi I, Wong J, Tugusheva K, Renger JJ, Zerbinatti C (2014) Intracellular clusterin interacts with brain isoforms of the bridging integrator 1 and with the microtubule-associated protein Tau in Alzheimer's disease. PLoS ONE 9:e103187

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

J.P.B was supported by grants from the Belgian Fonds de la Recherche Scientifique Médicale (T.0023.15, T0027.19), the Fund Aline (King Baudoin Foundation). JPB and KL were supported by the Belgian Alzheimer Research Foundation (SAO-FRA) (14001), and the Génicot Fund (ULB). C.D and M.C.P were supported by “Investissements d’avenir” of INSERM (ANR-10-IAIHU-06). CD was supported by France Alzheimer. K.S. is supported by the University of Antwerp Research Fund and SAO-FRA. The brain tissues were provided by the Brainbank NeuroCEB Neuropathology Network (funded by France Parkinson, ARSEP, CSC patients Associations, Fondation Vaincre Alzheimer, ARSLA, DFT France) and the NeuroLHNN biobank (BB190052). We thank Dr Sabrina Turbant for human tissue preparation and the NeuroCEB Neuropathology network: Dr Franck Letournel (CHU Angers), Dr Marie-Laure Martin-Négrier (CHU Bordeaux), Pr Françoise Chapon (CHU Caen), Pr Catherine Godfraind (CHU Clermont-Ferrand), Pr Claude-Alain Maurage (CHU Lille), Dr Vincent Deramecourt (CHU Lille), Dr David Meyronnet (CHU Lyon), Dr Nathalie Streichenberger (CHU Lyon), Dr André Maues de Paula (CHU Marseille), Pr Valérie Rigau (CHU Montpellier), Dr Fanny Vandenbos-Burel (Nice), Pr Charles Duyckaerts (CHU PS Paris), Pr Danielle Seilhean (CHU PS, Paris), Dr Susana Boluda (CHU PS, Paris), Dr Isabelle Plu (CHU PS, Paris), Dr Serge Milin (CHU Poitiers), Dr Dan Christian Chiforeanu (CHU Rennes), Pr Annie Laquerrière (CHU Rouen), Dr Béatrice Lannes (CHU Strasbourg). We also thank Dr Peter Davis (The Feinstein Institute for Medical Research, New York) for PHF1 antibody and Drs Masato Hasegawa and Michel Goedert (Cambridge, UK) for AP422 antibody.

Author information

Authors and Affiliations

  1. Laboratory of Histology, Neuroanatomy and Neuropathology, UNI (ULB Neuroscience Institute), Faculty of Medicine, Université Libre de Bruxelles, 808 route de Lennik, Bldg GE, 1070, Brussels, Belgium

    Kunie Ando, Robert De Decker, Cristina Vergara, Zehra Yilmaz, Salwa Mansour, Valérie Suain, Marie-Ange de Fisenne, Sarah Houben, Karelle Leroy & Jean-Pierre Brion

  2. Neurodegenerative Brain Diseases Group, VIB Center for Molecular Neurology, University of Antwerp, Universiteitsplein 1, 2610, Antwerp, Belgium

    Kristel Sleegers

  3. Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, and Inserm, U 1127, and CNRS UMR 7225, and ICM, 75013, Paris, France

    Marie-Claude Potier & Charles Duyckaerts

  4. Laboratoire de Neuropathologie Escourolle, Hôpital de La Pitié-Salpêtrière, AP-HP, Paris, France

    Charles Duyckaerts

  5. Department of Biological Science, Graduate School of Humanities and Sciences, Nara Women’s University, Nara, Japan

    Toshio Watanabe

  6. University of Lille, Inserm, CHU-Lille, Alzheimer and Tauopathies, LabEx DISTALZ, 59000, Lille, France

    Luc Buée

Authors
  1. Kunie Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert De Decker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cristina Vergara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zehra Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Salwa Mansour
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Valérie Suain
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kristel Sleegers
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marie-Ange de Fisenne
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sarah Houben
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Marie-Claude Potier
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Charles Duyckaerts
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Toshio Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Luc Buée
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Karelle Leroy
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Jean-Pierre Brion
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Kunie Ando or Jean-Pierre Brion.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (MP4 16763 kb)

Supplementary file2 (PDF 17148 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ando, K., De Decker, R., Vergara, C. et al. Picalm reduction exacerbates tau pathology in a murine tauopathy model. Acta Neuropathol 139, 773–789 (2020). https://doi.org/10.1007/s00401-020-02125-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00401-020-02125-x

Keywords

Search

Navigation